A Phase 1 interventional study of AZD3480 and Placebo in Alzheimer's Disease, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-07-02.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's planned enrollment of 52 is below the median of 70 across 2,808 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
AZD3480 + Aripiprazole
Drug: AZD3480 · Drug: Aripiprazole
Placebo + Aripiprazole
Drug: Placebo · Drug: Aripiprazole
AZD3480 capsules qd, oral, 22 days
Placebo qd, 12 days
single dose on day 5
Also known as: Abilify
PK variables
Time frame: Frequent sampling occasions during
Safety variables (adverse events, blood pressure, pulse, safety lab)
Time frame: During the whole treatment period
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca